Key Highlights
- Among the best performing mid-cap stocks on a weak market day, CG Oncology (NASDAQ:CGON) closed 13.95% higher on Monday, November 16, 2026.
- A hazard ratio of 0.32 came out of the Phase 3 PIVOT-006 trial, in which cretostimogene cut the risk of cancer recurrence by 68% compared with surveillance alone.
- Among the 367 patients enrolled, all with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, no grade 3 or higher treatment-related side effects were reported.
- For this population the company intends to file a second Biologics license application in the second quarter of 2027.
Trial Findings
Cretostimogene is a gene therapy built on a modified virus and delivered straight into the bladder, and PIVOT-006 tested it in patients whose tumors had been fully removed by surgery but who still face a meaningful risk of the cancer coming back. At about 90 sites in the United States and Canada, 367 patients were randomized to treatment or to surveillance, a common approach today for intermediate-risk disease. Recurrence risk fell by 68% with cretostimogene, with a hazard ratio of 0.32, a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001, a highly statistically significant result. As of October 26, 2026, median follow-up was 17 months. Safety formed a key part of the story. No grade 3 or higher treatment-related adverse events occurred, and no patients stopped treatment because of it, which matters for a population that is not facing an immediately life-threatening cancer and may be treated for long periods. The company called the improvement in recurrence-free survival unprecedented for this patient group, and full results will be shown as a late-breaking abstract at a major urology meeting on December 2, 2026. What sets this readout apart is the size of the effect together with consistent safety data, because earlier treatments for this population have often traded efficacy for side effects that limit how long patients stay on therapy.
The Commercial Significance
One of the most common cancers in the United States is non-muscle invasive bladder cancer, and many of those affected go through repeated recurrences and procedures over many years. After surgery, intermediate-risk patients have limited proven Options today, so a well-tolerated therapy that sharply cuts recurrence could address a large market. In a different, higher risk group, patients whose disease no longer responds to standard BCG therapy, CG Oncology is already seeking approval, backed by its BOND-003 trial. In that setting the drug holds Fast Track and Breakthrough Therapy designations, and the company plans to broaden its initial application to cover high-grade papillary-only disease, completing it before the end of March 2027. A second application in intermediate-risk and high-grade Ta disease would rest on the PIVOT-006 data and is planned for the second quarter of 2027. Manufacturing for both filings is complete, removing a common source of delay in biotech launches. Shares briefly changed hands more than 30% higher before the open and then eased to a 13.95% gain as the broader market sold off. If both applications are approved, opening a second, larger patient population materially changes the potential Revenue base for a company with a Market Value of several billion dollars.
What Investors Are Weighing Next
Milestones ahead include the December 2 presentation, which will Supply detail on subgroups and durability, as well as completion of the first application before the end of March 2027. Competition from other bladder cancer therapies, the price the company can command and the cost of building a commercial team are further matters for investors. Valuations in biotech stay sensitive to interest rates and market sentiment, even after strong data. Funding is another consideration, although positive data usually make it easier for companies to raise Capital on favourable terms ahead of a launch.
Where Things Stand
Once PIVOT-006 had shown a 68% cut in recurrence risk with a clean safety profile, CG Oncology rose 13.95%, and the next catalysts are the presentation on December 2 and regulatory filings in early and mid 2027.






Please wait processing your request...